Fresenius Medical Care AG: Form 20-F for the period ended Dec 31, 2018
Filed with the SEC on Feb 20, 2019 and accepted by EDGAR at Feb 20, 2019, 14:02 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2018-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2018-01-01 to 2018-12-31 | EUR 16.55bn | ifrs-full:Revenue |
| Cost of revenue | 12 months2018-01-01 to 2018-12-31 | EUR 11.39bn | ifrs-full:CostOfSales |
| Gross profit | 12 months2018-01-01 to 2018-12-31 | EUR 5.15bn | ifrs-full:GrossProfit |
| Operating income | 12 months2018-01-01 to 2018-12-31 | EUR 3.04bn | ifrs-full:ProfitLossFromOperatingActivities |
| Income tax | 12 months2018-01-01 to 2018-12-31 | EUR 511.1m | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Net income | 12 months2018-01-01 to 2018-12-31 | EUR 1.98bn | ifrs-full:ProfitLossAttributableToOwnersOfParent |
| Diluted EPS | 12 months2018-01-01 to 2018-12-31 | EUR 6.45 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months2018-01-01 to 2018-12-31 | EUR 6.47 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months2018-01-01 to 2018-12-31 | EUR 2.06bn | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months2018-01-01 to 2018-12-31 | −EUR 1.06bn | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | At period end2018-12-31 | EUR 2.15bn | ifrs-full:CashAndCashEquivalents |
| Current assets | At period end2018-12-31 | EUR 7.85bn | ifrs-full:CurrentAssets |
| Total assets | At period end2018-12-31 | EUR 26.24bn | ifrs-full:Assets |
| Current liabilities | At period end2018-12-31 | EUR 6.27bn | ifrs-full:CurrentLiabilities |
| Total liabilities | At period end2018-12-31 | EUR 13.34bn | ifrs-full:Liabilities |
| Shareholders' equity | At period end2018-12-31 | EUR 11.76bn | ifrs-full:EquityAttributableToOwnersOfParent |
| Shares outstanding | At period end2018-12-31 | 306,878,701 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001047469-19-000562. Last ingested by Listed: Nov 3, 2026, 10:24 ET. Listed shows no prices and gives no investment advice.